Sulodexide as a promising treatment of post COVID 19 symptomatic patients with endothelial dysfunction
 
More details
Hide details
1
Cardiology department, Hedi Chaker University Hospital Sfax, Tunisia Tunisia
 
2
Cardiology department, Habib Bourguiba Hospital Medenine, Tunisia
 
3
Cardiology department, Tahar Sfar Hospital Mahdia, Tunisia
 
4
Internal medicine department, Mongi Slim LaMarsa Hospital, Tunis, Tunisia Tunisia
 
5
Cardiology department, Habib Bourguiba Hospital Medenine, Tunisia Tunisia
 
6
Clinic Pasteur Tunis, Tunisia Tunisia
 
 
Publication date: 2023-04-26
 
 
Popul. Med. 2023;5(Supplement):A458
 
ABSTRACT
Background:
It is established that Covid 19 infection causes endothelial dysfunction resulting in most of its acute symptoms and its long-term effects also known as post covid-19 syndrome.

Aim:
The aim of the study was to evaluate the effect of Sulodexide, a purified glycosaminoglycan mixture, in the improvement of the endothelial function due to long COVID 19 syndrome.

Methods:
We conducted a multicenter Tunisian prospective quasi-experimental analysis from the large TUN End-COV trial. Patients with long COVID-19 symptoms and endothelial dysfunction were included. The subset of symptomatic patients with proven endothelial dysfunction (Endothelial Quality Index (EQI)

ISSN:2654-1459
Journals System - logo
Scroll to top